Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Open accessThe DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Abstract
Owing to their small size and safety profiles, adeno-associated viruses (AAVs) have become the vector of choice for gene therapy applications in the retina. In addition to the naturally occurring AAVs, several engineered variants with enhanced properties are being developed for experimental and therapeutic applications. Nonetheless, there are still some challenges impeding successful application of AAVs for a broader range of retinal gene therapies. The small size of AAV particles ensures efficient tissue transduction but also limits the packaging capacity to a few kilobases. Further, AAV's ability to cross retinal barriers is still an obstacle to pan-retinal transduction of the outer retina with tolerable doses. Lastly, despite overall safety, there have been recent reports of immune responses to AAVs in the eye. Hence, evaluation and prediction of immune responses to AAVs has come to be considered an integral part of future clinical success. This review focuses on the use of AAV in clinical trials for retinal diseases, and discusses developments of variants and novel strategies to overcome immune responses to AAVs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A significant barrier to effective intraocular rAAV gene delivery is the interaction of the vector with the host’s immune system [5].”
From Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“AMD has a global prevalence of close to 200 million and this number is bound to increase with an increase in elderly population overtime, making the development of therapy urgent.(20) AMD has two forms: dry and wet AMD.”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 2×
“BEs are DNA editing tools that use a dead Cas9 (dCas9; no/residual catalytic activity) fused with cytidine (CBEs) or adenine (ABEs) deaminases allowing single base conversion of C:G>T:A or A:T> G:C.(27,58) This strategy is particularly relevant in both monogenic autosomal recessive and autosomal dominant diseases cont…”
BackgroundNon-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 1×
“Non-viral vectors are a heterogenous family including various components such as lipid nanoparticles (LNPs), polymer-based vectors, or inorganic materials.(75,76) Nonetheless, when it comes to the retina, those vectors, which are bigger (~100–200nm) than AAVs (~25nm), may face numerous physical and physiological barri…”
BackgroundIn vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687 · cited 5×
“But, base and prime editors are too large to fit into a single AAV.(30) Although gene-editing techniques are precise and efficient, they are still known to have off-target effects.”
BackgroundInfluentialGenome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237 · cited 1×
“BEs were used recently in several cell types/organs, including the retina, and were delivered by dualAAVs approaches.(27,59) The delivery methods are usually based on trans-splicing inteins, where each part of the transgene containing split protein fused to N-terminal and C-terminal intein sequences.”
MethodEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“However, long-term follow-up in 2 out of 3 clinical trials reported a decline in the visual gains in adult patients, indicating that the treatment was unable to halt the degeneration.(15,19) This highlights two important aspects: the level of AAV transduction required for therapeutic benefits in humans may be higher a…”
BackgroundCRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404 · cited 1×
“The capsid proteins bind specific cell-surface receptors which in turn recruit coreceptors leading to internalization by endocytosis into the cell.(5) Following internalization AAVs escape the endosomes and gain entry into the nucleus.”
BackgroundGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“The proof-of-concept for vision restoration was provided in a canine model.(14) This led to clinical trials involving LCA2 patients who received SR injections of RPE65 packaged in AAV2 via SR delivery.”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 8×
“They reported that the elimination of CpG motifs from the ITRs did not affect the biological activity of AAVs.137 The use of these strategies, either independently or in combination, can result in improved gene delivery in the presence of antibodies and facilitate repeat AAV injections.”
BackgroundInfluential
Cited by
Nucleic acid-based drugs for patients with solid tumours
Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E., & Sorscher, E. J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00883-1 · Cited by 61
Agrahari, V., Choonara, Y. E., Mosharraf, M., Patel, S. K., & Zhang, F. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03798-9 · Cited by 61
“Similarly, with Adeno-Associated Viruses (AAVs) for gene delivery, AI algorithms that can reduce the AAV discovery cycle by generating new libraries and selecting variants that increase the success rate of AAVs have been proposed [20].”
Combined AAV-mediated specific Gjb2 expression restores hearing in DFNB1 mouse models
Sun, Q., Tan, F., Zhang, L., Lu, Y., Hao, W., Li, N., Jiang, L., Zhou, Y., Chen, T., Ling, L., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.029 · Cited by 43
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
“A goodcapsid variant possesses immensecommercialvalue and holds promising prospects for application 13,51 .”
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 34
“Clinically, AAV has a solid track record and has been extensively used in gene therapy trials (Ail et al., 2023; Muramatsu and Muramatsu, 2023).”
MethodPanwar, R., Mishra, A., Sahu, A., Quadri, S. N., Abdin, M. Z., & Fatima, S. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-025-03308-z · Cited by 29
“In gene-delivery systems such as AAVs, ML enables rapid screening and identification of variants with improved targeting and stability [77].”
Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies
Xia, X., & Guo, X. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1310050 · Cited by 25
The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis
Liu, Z., Zhang, H., Jia, H., Wang, H., Huang, Z., Tang, Y., Wang, Z., Hu, J., Zhao, X., Li, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112265 · Cited by 22
“56 59 AAV2.”
Poller, W. C., Sahoo, S., Hajjar, R. J., Landmesser, U., & Krichevsky, A. M. (2023) · Cells · doi:10.3390/cells12222660 · Cited by 22
“From previous studies, it is well known that genetic engineering of the vector surface i.e., pseudotyping has, in principle, the capacity to alter tropism in a desired direction [248,250,291,292,300,301].”
BackgroundChen, H., LaFlamme, C. W., Wang, Y., Blan, A. W., Koehler, N., Moraes, R. M., Olszewski, A. R., Fuerte, E. P. A., Bonkowski, E. S., Bajpai, R., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn8417 · Cited by 21
The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2
Cui, M., Su, Q., Yip, M., McGowan, J., Punzo, C., Gao, G., & Tai, P. W. L. (2024) · Gene Therapy · doi:10.1038/s41434-024-00477-7 · Cited by 20
Viral vector‐based gene therapies in the clinic: An update
Park, K. S., Cho, Y., Mitragotri, S., & Zhao, Z. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70106 · Cited by 19
“61,62 For blood disorders, AAV5 is the most frequently used serotype, followed by AAV8, aligning with liver-directed gene transfer strategies for systemic protein replacement.”
Meierrieks, F., Weltken, A., Pflanz, K. B., Pickl, A., Graf, B., & Wolff, M. W. (2024) · Biotechnology Journal · doi:10.1002/biot.202400430 · Cited by 16
“Among these, adeno-associated virus (AAV) vectors have emerged as particularly promising for in vivo gene therapy [2, 3], due to their nonpathogenicity [4], low immunogenicity [5], ease of production [6], and transgene”
Simons, E. J., & Trapani, I. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.126 · Cited by 14
“1,13,15 The findings that some variants, which resulted in improved tropism in small-animal models, have failed to achieve similar results in nonhuman primates, 13,16 have led to further refinement in the design and screening processes used for selection and isolation of improved variants.”
Som, M., Gikanga, B., Kanapuram, V., & Yadav, S. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.03.024 · Cited by 13
Clerck, K. D., Smedt, S. C. D., Remaut, K., & Peynshaert, K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113849 · Cited by 11
AAV-mediated gene therapy for sialidosis
van de Vlekkert, D., Hu, H., Weesner, J. A., Fremuth, L. E., Brown, S. A., Lu, M., Gomero, E. M., Campos, Y., Sheppard, H., & d’Azzo, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.029 · Cited by 11
Najafi, S., Rahimpour, A., Ahmadieh, H., Tehrani, M. M., Khalilzad, M. A., Suri, F., & Ranjbari, J. (2024) · Electronic Journal of Biotechnology · doi:10.1016/j.ejbt.2024.07.005 · Cited by 11
Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells
Patra, A. T., Tan, E., Kok, Y. J., Ng, S. K., & Bi, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101278 · Cited by 8
Shim, J., Kim, Y., Bak, J., Shin, S. H., Lee, K., Hwang, Y. H., Kong, H. Y., & Han, J. S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101366 · Cited by 8
Meierrieks, F., Rosario, J.-C., Rübeling, L., Asikoglu, H. C., Pflanz, K. B., Pickl, A., Kusch, K., Wolff, M. W., & Graf, B. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.465674 · Cited by 7
Ocular Delivery of Viral Vectors for Retinal and Choroidal Vascular Diseases: A Review
Agrawal, R., Oraskovich, S. V., Francis, P. J., & Schaffer, D. V. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.07.025 · Cited by 7
Cai, Y., Gu, Y., Zhang, J., Zhu, Y. Y., Ma, Z., He, Q., Sun, Y. J., Yuan, M., Li, X., Zhu, K., et al. (2025) · Research · doi:10.34133/research.0717 · Cited by 6
“7m8 and 4D-R100 [ 29 ].”
Emerging strategies targeting genes and cells in glaucoma
Roy, S. (2024) · Vision Research · doi:10.1016/j.visres.2024.108533 · Cited by 6
Diress, M., Ionescu, C. M., Foster, T., Lim, P., Sen, L. Y., Kovačević, B., Wagle, S. R., Mooranian, A., & Al‐Salami, H. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107172 · Cited by 5
Gong, X., & Hertle, R. W. (2024) · Life · doi:10.3390/life14111356 · Cited by 4
Lombardi, L., Petoe, M. A., Moussallem, L., Kolic, M., Baglin, E. K., Stefopoulos, S., Battiwalla, X., Walker, J. G., Barnes, N. M., Abbott, C. J., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.5.11 · Cited by 4
Stone, M. L., Lee, H. H., & Levine, E. M. (2024) · iScience · doi:10.1016/j.isci.2024.111299 · Cited by 4
“20,21 24 However, electroporation requires that cells or tissues be submerged in buffer with an electrode to allow electric current flow and that direct contact between the tissue and electrodes is avoided.”
Ross, M., Sade, K., Obolensky, A., Averbukh, E., Desrosiers, M., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00495-5 · Cited by 3
Self-citationToward improved AAV gene therapies for retinal disorders: challenges and advances
Siontas, O., Brown, M., & Ahn, S. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2544497 · Cited by 3
Wu, J., Jang, H., Kwak, H., Son, M., Jiang, W., Hwang, H., Jo, D. H., Kim, D., Kim, S., & Kim, J. H. (2025) · Genome biology · doi:10.1186/s13059-025-03774-5 · Cited by 3
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease
Zhu, S., Zhang, J., Jiang, X., Peng, C., Liu, H., & Qian, F. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115773 · Cited by 3
Wei, S. C., Cantor, A. J., Walleshauser, J., Mepani, R. J., Melton, K., Bans, A., Khekare, P., Gupta, S., Wang, J., Soares, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317387 · Cited by 3
“…is that the large size of the cDNA encoding proteins involved in many IRDs far exceeds the packaging capacity of established delivery vectors [21]; for example, the cDNA sizes for replacement of ABCA4 (Stargardt disease) and USH2A (Usher syndrome) are 6,819 bp and 15,606 bp, respectively,…”
Moon, T. K., Kang, I. K., Lee, K. J., Kim, J. H., Kim, H. J., Han, A. R., Woo, H., Lee, J. Y., Choi, J., Park, K., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101404 · Cited by 2
“9,10 Current efforts are focused on delivering genes that can modulate therapeutic proteins directly within the eye, potentially eliminating the need for repeated treatments.”
VEGFA-Targeted M3-F4 Ionizable Lipid Nanoparticles Improve Diabetic Retinopathy
Liu, S., Bao, Y., Yilihaer, Y., Guo, W., Ma, C., Xue, C., Yang, Z., Chen, Y., & Xie, Z. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00026 · Cited by 2
Cui, M., Cheng, S.-Y., Liang, J., McGowan, J., Xu, M., Xu, G., Luo, L., Wu, J., Harman, C. D., Jacobson, A. L., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.029 · Cited by 1
AI-INTEGRATED NANOMEDICINE: DISCOVERY, DESIGN, AND CLINICAL TRANSLATION
More, R. (2025) · Iterative International Publishers eBooks · doi:10.58532/nbennurradc2n1 · Cited by 1
Bridging the gap: an emerging link between tubulinopathies and ciliopathies
Steiman, S., Omer, S., Pastore, S., & Ivakine, E. A. (2026) · npj Genomic Medicine · doi:10.1038/s41525-026-00576-x · Cited by 1
“In the treatment of ciliopathies, AAV-based delivery has shown pro-miseintheretina,particularlyforLebercongenitalamaurosis,butextending thissuccesstootheraffectedorganssuchasthekidneyandlungsremains dif fi cult 190,192 – 194 .”
Eghtesad, M. (2024) · TSpace (University of Toronto)
Precision Medicine in Inherited Retinal Disease: Advances, Challenges, and Future Directions
Dhivagaran, T., Butt, F. R., Grover, K., Devgan, K., Sachdeva, K. S., Dhivagaran, V., Abid, F., Tao, B. K.-L., Balas, M., Dimopoulos, I. S., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060292
“In some cases, the introduction of viral vectors can activate the immune response and cause inflammation, leading to a potential reduction in efficacy [52].”
InfluentialHasegawa, T., Vridhachalam, N., Nikolai, E. S., Kalikiri, T., Ross, M., Toennisson, R., Villanueva, P., Chandler, A. M., Song, L., Bower, J. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.10.737493
Restorative and regenerative therapies for vision loss
Boychev, N., Soucy, J. R., Dang, S. H., Tran, C. T., Malkin, A. G., Yeung, V., Ross, A. E., Hutcheon, A. E. K., & Kanu, L. N. (2026) · Eye · doi:10.1038/s41433-026-04913-3
Artificial Intelligence as a Catalyst for Cell-Based Therapies in Retinal Disease
Srivastava, G. K., Shukla, P., Millas, S. C., & Lokanathan, Y. (2026) · Cells · doi:10.3390/cells15201887
“Critically, gene therapy can preserve or rescue surviving cells but cannot restore those already lost, rendering it ineffective in patients presenting with advanced degeneration [40].”
Influential
Metadata
- Authors
- Ail, D., Malki, H., Zin, E. A., & Dalkara, D.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Ail, Divya
- Malki, Hugo
- Zin, Emilia A
- Dalkara, Deniz
- Venue
- The Application of Clinical Genetics
- Publisher
- Informa UK Limited
- Published
- 2023-05
- Volume
- Volume 16
- Pages
- 111-130
- ISSN
- 1178-704X (ISSN-L)
- PMC
- PMC10239239
- OpenAlex
- W4379377001
- Cited by
- 40
- References
- 139
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 17 · 2023: 3
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Application of Clinical Genetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, retinal gene therapy, adeno-associated virus vectors, retinal transduction, outer retina, retinal disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.